Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies

T. K. Kvien; A. Deodhar; L. Gossec; P. G. Conaghan; V. Strand; Mikkel Østergaard; N. Williams; B. Porter; K. Gandhi; S. Jugl

Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies

T. K. Kvien, A. Deodhar, L. Gossec, P. G. Conaghan, V. Strand, Mikkel Østergaard, N. Williams, B. Porter, K. Gandhi, S. Jugl

Afdeling for Rygkirurgi, Led- og Bindevævssygdomme

Originalsprog	Engelsk
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	76
Udgave nummer	Suppl 2
Sider (fra-til)	355-356
Antal sider	2
ISSN	0003-4967
Status	Udgivet - 2017

Citationsformater

Kvien, T. K., Deodhar, A., Gossec, L., Conaghan, P. G., Strand, V., Østergaard, M., Williams, N., Porter, B., Gandhi, K., & Jugl, S. (2017). Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies. Annals of the Rheumatic Diseases, 76(Suppl 2), 355-356.

Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies. / Kvien, T. K.; Deodhar, A.; Gossec, L. et al.
I: Annals of the Rheumatic Diseases, Bind 76, Nr. Suppl 2, 2017, s. 355-356.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Kvien, TK, Deodhar, A, Gossec, L, Conaghan, PG, Strand, V, Østergaard, M, Williams, N, Porter, B, Gandhi, K & Jugl, S 2017, 'Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies', Annals of the Rheumatic Diseases, bind 76, nr. Suppl 2, s. 355-356.

@article{9bf178cf743e495e8783d8acf771c8ac,

title = "Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies",

author = "Kvien, {T. K.} and A. Deodhar and L. Gossec and Conaghan, {P. G.} and V. Strand and Mikkel {\O}stergaard and N. Williams and B. Porter and K. Gandhi and S. Jugl",

note = "COPECARE",

year = "2017",

language = "English",

volume = "76",

pages = "355--356",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "Suppl 2",

}

TY - ABST

T1 - Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies

AU - Kvien, T. K.

AU - Deodhar, A.

AU - Gossec, L.

AU - Conaghan, P. G.

AU - Strand, V.

AU - Østergaard, Mikkel

AU - Williams, N.

AU - Porter, B.

AU - Gandhi, K.

AU - Jugl, S.

N1 - COPECARE

PY - 2017

Y1 - 2017

M3 - Conference abstract in journal

SN - 0003-4967

VL - 76

SP - 355

EP - 356

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 2

ER -